Prediction of Biological Characteristics of Breast Cancer Using Dual-phase FDG PET/CT

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2019 Jan 17

PMID 30648199

Citations 6

Authors

Shinsuke Sasada

Norio Masumoto

Eri Suzuki

Satoshi Sueoka

Noriko Goda

Keiko Kajitani

Akiko Emi

Takayuki Kadoya

Morihito Okada

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to assess whether the retention index (RI) determined using dual-phase F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) reflects the malignant features of breast cancer.

Methods: A total of 1,523 patients with breast cancer were retrospectively evaluated. PET/CT scans were performed at 1 h and 2 h after FDG administration before treatment. The maximum standardized uptake value (SUVmax) at both time points (SUVmax1 and SUVmax2) in the primary tumour and RI were calculated. Primary tumour tissues were evaluated in terms of biological features, such as histology, nuclear grade, lymphovascular invasion and molecular subtype.

Results: Of the 1,523 patients, 463 (30.4%) had luminal A-like, 661 (43.4%) had luminal B-like, 229 (15.0%) had human epidermal growth factor receptor 2-positive (HER2-positive), and 157 (10.3%) triple-negative breast cancer. The median SUVmax1, SUVmax2 and RI values were 2.2, 2.3 and 2.6%, respectively. These metabolic parameters were correlated with tumour size, nodal metastasis, histology, nuclear grade, lymphovascular invasion, and molecular subtype (all P < 0.001). The median RI values were 0% in luminal A-like, 5.3% in luminal B-like, 6.9% in HER2-positive, and 11.4% in triple-negative breast cancer. RI was associated with malignant features when the tumour accumulated a significant amount of FDG. In a subanalysis of patients with tumours of stages T2 to T4, RI was correlated with nodal metastasis, histology, nuclear grade, and molecular subtype (luminal A-like 4.8%, luminal B-like 12.3%, HER2-positive 15.8%, and triple-negative 16.3%).

Conclusion: RI determined using delayed-phase FDG PET/CT is associated with malignant features in breast cancers with significant FDG uptake. Dual-phase imaging was helpful in distinguishing luminal A-like breast cancer from luminal B-like, HER2-positive, and triple-negative breast cancers.

Citing Articles

Comparative analysis of metabolic characteristics and prognostic stratification of HER2-low and HER2-zero breast cancer using F-FDG PET/CT imaging.

Gao Y, Yin L, Ma L, Wu C, Zhu X, Liu H Cancer Imaging. 2024; 24(1):166.

PMID: 39695831 PMC: 11653929. DOI: 10.1186/s40644-024-00812-6.

Imaging Molecular Targets and Metabolic Pathways in Breast Cancer for Improved Clinical Management: Current Practice and Future Perspectives.

Ndlovu H, Lawal I, Mokoala K, Sathekge M Int J Mol Sci. 2024; 25(3).

PMID: 38338854 PMC: 10855575. DOI: 10.3390/ijms25031575.

The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis.

de Mooij C, Ploumen R, Nelemans P, Mottaghy F, Smidt M, van Nijnatten T EJNMMI Res. 2023; 13(1):5.

PMID: 36689007 PMC: 9871105. DOI: 10.1186/s13550-023-00953-y.

Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer.

Mao J, Gao M, Cui B, Zhang Y, Wang X, Liang S Molecules. 2022; 27(14).

PMID: 35889531 PMC: 9318552. DOI: 10.3390/molecules27144661.

Diagnostic performance of dedicated breast positron emission tomography.

Hashimoto R, Akashi-Tanaka S, Watanabe C, Masuda H, Taruno K, Takamaru T Breast Cancer. 2022; 29(6):1013-1021.

PMID: 35768684 PMC: 9587931. DOI: 10.1007/s12282-022-01381-x.

References

Boerner A, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U . Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999; 26(3):226-30. DOI: 10.1007/s002590050381. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Kumar R, Loving V, Chauhan A, Zhuang H, Mitchell S, Alavi A . Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005; 46(11):1819-24. View

Soret M, Bacharach S, Buvat I . Partial-volume effect in PET tumor imaging. J Nucl Med. 2007; 48(6):932-45. DOI: 10.2967/jnumed.106.035774. View

Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn H . Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007; 18(7):1133-44. DOI: 10.1093/annonc/mdm271. View

Ueda S, Tamaki Y, Yano K, Okishiro N, Yanagisawa T, Imasato M . Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast. Surgery. 2008; 143(3):414-25. DOI: 10.1016/j.surg.2007.10.006. View

Groheux D, Giacchetti S, Moretti J, Porcher R, Espie M, Lehmann-Che J . Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2010; 38(3):426-35. DOI: 10.1007/s00259-010-1640-9. View

Garcia Vicente A, Soriano Castrejon A, Relea Calatayud F, Palomar Munoz A, Leon Martin A, Chacon Lopez-Muniz I . 18F-FDG retention index and biologic prognostic parameters in breast cancer. Clin Nucl Med. 2012; 37(5):460-6. DOI: 10.1097/RLU.0b013e31823926c9. View

Garcia Vicente A, Soriano Castrejon A, Relea Calatayud F, Munoz Madero V, Molina Garrido M, Leon Martin A . 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol. 2012; 31(6):308-14. DOI: 10.1016/j.remn.2011.12.001. View

10.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

11.

Groheux D, Espie M, Giacchetti S, Hindie E . Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2012; 266(2):388-405. DOI: 10.1148/radiol.12110853. View

12.

Hong S, Li J, Wang S . 18FDG PET-CT for diagnosis of distant metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013; 22(2):139-43. DOI: 10.1016/j.suronc.2013.03.001. View

13.

Garcia Vicente A, Soriano Castrejon A, Leon Martin A, Chacon Lopez-Muniz I, Munoz Madero V, Mar Munoz Sanchez M . Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(9):1304-11. DOI: 10.1007/s00259-013-2418-7. View

14.

Ekmekcioglu O, Aliyev A, Yilmaz S, Arslan E, Kaya R, Kocael P . Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma. Nucl Med Commun. 2013; 34(11):1055-67. DOI: 10.1097/MNM.0b013e3283658369. View

15.

Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M . Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat. 2013; 141(2):269-75. PMC: 3785187. DOI: 10.1007/s10549-013-2687-7. View

16.

Moon H, Noh W, Kim H, Kim E, Park K, Lee S . The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. Nucl Med Mol Imaging. 2016; 50(3):246-54. PMC: 4977256. DOI: 10.1007/s13139-016-0412-2. View

17.

Ozen A, Altinay S, Ekmekcioglu O, Albayrak R, Muhammedoglu A, Yigitbas H . Dual-Time F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors. Indian J Surg. 2016; 78(5):382-389. PMC: 5127986. DOI: 10.1007/s12262-016-1486-x. View

18.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

19.

Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-1712. PMC: 6246241. DOI: 10.1093/annonc/mdx308. View

20.

Hamberg L, Hunter G, Alpert N, Choi N, Babich J, Fischman A . The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med. 1994; 35(8):1308-12. View